The Impact of Gastric Bypass on Gastroesophageal Reflux Disease in Morbidly Obese Patients
Autor: | Richard Ricachenevsky Gurski, Sidia M. Callegari-Jacques, Carlos Augusto Scussel Madalosso, Guilherme S. Mazzini, Daniel Navarini, Marina da Silva Pereira |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Gastric bypass Gastric Bypass 030209 endocrinology & metabolism Disease Morbidly obese Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine medicine Humans Prospective Studies Young adult Prospective cohort study business.industry Reflux Middle Aged medicine.disease humanities digestive system diseases Obesity Morbid Early results GERD Gastroesophageal Reflux 030211 gastroenterology & hepatology Surgery Female business |
Zdroj: | Annals of surgery. 263(1) |
ISSN: | 1528-1140 |
Popis: | To assess the impact of Roux-en-Y gastric bypass (GBP) on gastroesophageal reflux disease (GERD) in morbidly obese patients.Recently, authors have reported that early results of GBP can control GERD. However, longer follow-ups based on objective parameters for GERD are missing.Fifty-three patients [15 men (28%), 39 years old (range, 18-59), body mass index = 46 ± 7.7 kg/m2] were consecutively evaluated for GERD irrespectively of related symptoms, before the operation (E1) and at 6 (E2) and 39 ± 7 months postoperatively (E3). The end points were (1) esophageal syndromes based on the Montreal Consensus and (2) an esophageal acid exposure assessment.Body mass index dropped from 46 ± 7.7 kg/m2 at E1 to 30 ± 5.2 kg/m2 at E3. Typical reflux syndrome displayed a significant decrease from 31 (58%) at E1 to 8 (15%) at E2 and 5 (9%) at E3. Statistically significant differences occurred between E1 and both postoperative evaluations (P0.001). Reflux esophagitis was detected in 24 (45%), 17 (32%), and 10 patients (19%) at E1, E2, and E3, respectively (P = 0.002). The incidence of GERD decreased in 34 (64%) and 21 (40%) patients at E1 and E2, respectively, and then in 12 (23%) patients at E3. DeMeester scores reduced from 28.6 (E1) to 9.4 (E2) and 1.2 (E3) (P0.001).For most morbidly obese patients, in addition to causing significant weight loss, GBP reduces GERD symptoms, improves reflux esophagitis, and decreases esophageal acid exposure for longer than 3 years. |
Databáze: | OpenAIRE |
Externí odkaz: |